Genentech, Inc.
Clinical trials sponsored by Genentech, Inc., explained in plain language.
-
Experimental CAR-T therapy takes on tough lupus cases
Disease control Not yet recruitingThis early-stage trial tests a new treatment called P-CD19CD20-ALLO1, a type of CAR-T cell therapy, for people with severe lupus that hasn't improved with standard treatments. The study will enroll 162 participants and aims to check if the therapy is safe and tolerable. It also l…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New daily pill could help breast cancer patients who Can't tolerate standard hormone drugs
Disease control Not yet recruitingThis phase 3 trial is testing a daily pill called giredestrant in 300 people with ER+/HER2- early breast cancer who had to stop standard aromatase inhibitors due to side effects. The study will track how well patients stick with the treatment, their quality of life, and any side …
Phase: PHASE3 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cevostamab enters early human testing for lupus
Disease control Not yet recruitingThis early-stage trial will test the safety and tolerability of a new drug, cevostamab, in 46 people with systemic lupus erythematosus, some of whom also have active lupus nephritis. The drug is given intravenously, and researchers will monitor side effects and how the drug moves…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
MS patients may soon get a simpler shot option
Disease control Not yet recruitingThis study looks at whether people with multiple sclerosis can safely switch from their current anti-CD20 therapy to a new under-the-skin version of ocrelizumab. About 100 participants will be followed for up to 48 weeks to see if brain lesions stay stable and if they are satisfi…
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC